Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Peking University
- Target Recruit Count
- 180
- Registration Number
- NCT03575637
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 156
- Registration Number
- NCT03571126
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-07-16
- Target Recruit Count
- 44
- Registration Number
- NCT03568500
- Locations
- 🇬🇧
Clinical Trial Site, Southampton, United Kingdom
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1260
- Registration Number
- NCT03510325
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 130
- Registration Number
- NCT03478605
- Locations
- 🇷🇺
N.N. Blokhin Cancer Research Center, Moscow, Russian Federation
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- University of Rochester NCORP Research Base
- Target Recruit Count
- 1351
- Registration Number
- NCT03367572
- Locations
- 🇺🇸
Health Partners Inc, Minneapolis, Minnesota, United States
🇺🇸Hawaii MU NCORP, Honolulu, Hawaii, United States
🇺🇸Decatur Memorial Hospital, Decatur, Illinois, United States
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2020-03-31
- Target Recruit Count
- 100
- Registration Number
- NCT03304457
- Locations
- 🇮🇳
AIIMS, Bhubaneshwar, Odisha, India
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 119
- Registration Number
- NCT03230864
- Locations
- 🇧🇬
DCC St. Vrach and St.St. Kuzma and Damian, Sofia, Bulgaria
🇧🇬MHC - Sofia, Sofia, Bulgaria
🇧🇬UMHAT, Pleven, Bulgaria
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2019-08-20
- Target Recruit Count
- 240
- Registration Number
- NCT03219710
- Locations
- 🇮🇳
Dr Bra Irch, Aiims, New Delhi, New Delhi, Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.